BrainChip Holdings (ASX: BRN) has entered a global, non-exclusive licensing agreement with EDGEAI for its Akida 2 neuromorphic IP.
The agreement is comprehensive, granting EDGEAI access to Akida IP, integration documentation, development tools, software components, hardware support materials, and engineering assistance for design, verification, and integration.
Compensation for BrainChip is structured around milestone-based payments, linked to the staged delivery of technical assets and services.
Importantly, ongoing royalties will be payable quarterly after EDGEAI's commercial shipments commence, calculated as a percentage of product sales price.
While the licence remains active for as long as EDGEAI continues to use the Akida IP, EDGEAI retains the ability to terminate the agreement without cause on one month’s written notice.
BrainChip has stated it cannot quantify the financial impact at this time, though it expects royalties to be material over time depending on EDGEAI product volume.
Annual Report Shows Production Progress
BrainChip's 2025 Annual Report, released on 26 February 2026, detailed significant operational advancements.
The company reported that its AKD1500 had moved to tape-out and volume production, with production silicon anticipated in Q3 2026.
Financially, BrainChip saw its revenue increase 374% to US$1.89 million in 2025, up from US$398,011 in 2024.
The net loss after tax also improved, reducing to US$20.47 million in 2025 from US$24.43 million in the previous year.
Post year-end, on 13 February 2026, BrainChip initiated the AKD2500 custom silicon development project.
Prototype silicon for the AKD2500 is expected in Q3 2026, further advancing its next-generation technology roadmap.
Financial Position Strengthened
The company’s financial runway was significantly bolstered during 2025.
Cash and cash equivalents increased to US$31.71 million at year-end 2025, up from US$20.00 million in 2024.
A substantial A$37 million equity raise in November 2025 further strengthened BrainChip's capital position.
This raise comprised a A$35 million underwritten placement and a A$2 million Share Purchase Plan.
Furthermore, the LDA Put Option Agreement renewal maintains a total funding commitment of A$140 million.
A minimum drawdown of A$20 million from this facility is due no later than 30 June 2026.
Commercial Ecosystem Expansion
BrainChip highlighted expanded partnerships and engagements across several key sectors, including aerospace and defence, wearable technology, and industrial IoT connectivity.
These collaborations aim to integrate Akida technology into emerging edge AI markets.
Developer enablement remains a focus for BrainChip, with the launch of the MetaTF 2.13 developer hub and Developer Akida Cloud.
These platforms provide hardware-free access to Akida 2, assisting developers in integrating the technology.
Previous commercial engagements include a US$1.8 million contract with Raytheon for neuromorphic radar signal processing, secured in December 2024 under the US Air Force Research Laboratory (AFRL) SBIR program.
Outlook and Risks
The EDGEAI licensing agreement provides a potential new revenue stream through royalties, contingent on EDGEAI's product success.
However, BrainChip's dependence on external funding and the inherent risks in commercialising new technology.
Product development timing and customer adoption delays, as highlighted in its annual report, remain key investor considerations.
